Eton Pharmaceuticals, Inc. ETON License — Revenue
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Eton Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Eton Pharmaceuticals, Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about Eton Pharmaceuticals, Inc.'s license — revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Eton Pharmaceuticals, Inc.'s license — revenue?
- Eton Pharmaceuticals, Inc. (ETON) reported license — revenue of $0 in Q1 2026.
- How has Eton Pharmaceuticals, Inc.'s license — revenue changed year-over-year?
- Eton Pharmaceuticals, Inc.'s license — revenue decreased by 100.0% year-over-year, from $3.29M to $0.
- What is the long-term trend for Eton Pharmaceuticals, Inc.'s license — revenue?
- Over 4 years (2021 to 2025), Eton Pharmaceuticals, Inc.'s license — revenue has grown at a -35.5% compound annual growth rate (CAGR), from $19M to $3.29M.
- What does license — revenue mean?
- Represents the total gross revenue recognized from licensing agreements, excluding any collected sales taxes. This metric captures the core income generated from granting third parties the rights to utilize the company's intellectual property or pharmaceutical assets. It serves as a primary indicator of the commercial success and market demand for the company's licensed portfolio.